System readiness and the patient care pathway for Alzheimer's disease diagnosis and treatment
Promising therapeutic interventions that target the underlying pathophysiology are changing the landscape of Alzheimer's disease (AD) research. The AD care pathway must be transformed to meet the challenge of bringing these new therapies to the increasing number of people living with AD within the existing healthcare framework. Challenges include identifying patients who may benefit from treatment interventions early in the course of the disease, ensuring that diagnostic tools are accessible and accurate, and developing capabilities to monitor the effectiveness of interventions over time. These challenges must be addressed at all levels, from primary care settings to tertiary treatment centers; this will require collaborative efforts between health systems, drug manufacturers, and research institutions to navigate this evolving landscape and ensure system readiness for patients and their families with AD. The Spring 2024 Alzheimer's Association Research Roundtable (AARR) meeting gathered industry representatives and clinicians to discuss insights, challenges, and solutions that will help researchers and health systems identify patients in the early stages of AD and deliver emerging therapies efficiently and safely. In this paper, we provide highlights from the Spring 2024 AARR meeting.
Authors
- Simin Mahinrad (ORCID: https://orcid.org/0000-0002-5927-7130)
- Debjani Mukherjee (ORCID: https://orcid.org/0000-0002-8233-8608)
- Darren R. Gitelman (ORCID: https://orcid.org/0000-0001-6057-5605)
- Soeren Mattke (ORCID: https://orcid.org/0000-0003-4666-9132)
- María C. Carrillo (ORCID: https://orcid.org/0000-0003-3057-2387)
- Rachel Kolster
- G Walker (ORCID: https://orcid.org/0000-0002-3883-8816)
- Christopher J. Weber
- Alessandro Biffi (ORCID: https://orcid.org/0000-0001-7063-455X)
- Gil Dan Rabinovici (ORCID: https://orcid.org/0000-0002-3626-4265)
- Sasha Bozeat
- Dorene M. Rentz (ORCID: https://orcid.org/0000-0002-6318-9213)
- Gill Farrar (ORCID: https://orcid.org/0000-0002-0726-723X)
- Michelle M. Mielke (ORCID: https://orcid.org/0000-0001-7177-1185)
- Hamid Reza Okhravi (ORCID: https://orcid.org/0009-0006-3684-5357)
- José Soria (ORCID: https://orcid.org/0000-0002-0933-6163)
- Jennifer Murphy (ORCID: https://orcid.org/0000-0003-2751-184X)
- B. Joy Snider
- Carolyn Clevenger
- Heather Synder
Institutions
- Roche (Switzerland) (CH)
- Alzheimer's Association (US)
- Brigham and Women's Hospital (US)
- Biogen (United States) (US)
- Johnson & Johnson (United States) (US)
- Harvard University (US)
- Emory University (US)
- Eastern Virginia Medical School (US)
- Eli Lilly (United States) (US)
- University of California, San Francisco (US)
- Washington University in St. Louis (US)
- UC San Diego Health System (US)
- Buckinghamshire Healthcare NHS Trust (GB)
- Advocate Lutheran General Hospital (US)
- University of California San Diego (US)
- University Memory and Aging Center (US)
- Hope Center for Neurological Disorders (US)
- Precision Research Institute (US)
- Janssen (United States) (US)
- Wake Forest University (US)
Publication Details
- Journal
- Alzheimer s & Dementia Translational Research & Clinical Interventions
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1002/trc2.70094
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00